Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Renal Cell Carcinoma
Advertisement
Latest News
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.
Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Most patients in EMBARK recovered testosterone after treatment break, regardless of therapy or age.